Qyuns Therapeutics (SEHK:2509) Profitability Shift Challenges Bearish Earnings Narratives

Qyuns Therapeutics (SEHK:2509) has just posted its FY 2025 numbers, headlined by first half revenue of C¥206.5 million and a basic EPS loss of C¥0.13, while the latest trailing twelve month figures show revenue of C¥806.9 million and basic EPS of C¥1.41 as the business moved into profit over the period. Over the last three reported halves, revenue has stepped up from C¥44.9 million in 1H 2024 to C¥113.9 million in 2H 2024 and then to C¥206.5 million in 1H 2025, with net income swinging from losses of C¥172.1 million and C¥163.5 million in 1H and 2H 2024 respectively to a trailing twelve month profit of C¥307.4 million. That puts the focus firmly on how durable these margin gains really are for shareholders.

See our full analysis for Qyuns Therapeutics.

With the headline results set, the next step is to see how these margin shifts and the move into profitability line up with the main narratives investors follow around Qyuns Therapeutics.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM profit of C¥307.4 million contrasts with recent half loss

• Over the last twelve months Qyuns reported net income of C¥307.4 million, while 1H 2025 alone still shows a loss of C¥28.3 million on revenue of C¥206.5 million. This indicates that the recent profit came from earlier halves rather than this latest period.
• Bulls highlight that the company became profitable over the last year with average earnings growth of 34.4% per year over five years. However, the shift from a C¥191.8 million trailing twelve month loss at 1H 2025 to a C¥307.4 million profit by the latest half means investors need to distinguish the one year track record from the shorter term swing in earnings.
  • That five year earnings growth figure aligns with the C¥806.9 million in trailing twelve month revenue, which is much higher than any single half year revenue point such as the C¥206.5 million reported in 1H 2025.
  • At the same time, the loss in 1H 2025 and earlier half year losses of C¥172.1 million and C¥163.5 million in 1H and 2H 2024 show that periods of negative net income can still appear within that longer term growth story.

P/E of 12.5x sits well below biotech peers

• The shares trade at a trailing P/E of 12.5x compared with 39.4x for the Asian Biotechs industry and 15x for peers, so on this metric the stock is priced lower than both groups while still based on trailing twelve month EPS of C¥1.41.
• Some bearish arguments note that forecasts call for a 31.2% per year earnings decline over the next three years. Even so, the current valuation still reflects a discount to peers and the wider industry on the same earnings base.
  • Critics focus on that forecast decline in earnings, but the market price of HK$19.38 against a DCF fair value of HK$37.12 shows a wide gap that is not explained by P/E alone.
  • For readers comparing risk and reward, the combination of a 12.5x P/E and a share price well below the DCF fair value highlights how strongly the data support the value case, even while the earnings outlook is cautious.

Stay on top of how value arguments and cautionary views stack up as new data lands by checking what other investors are saying in real time 📊 Read the what the Community is saying about Qyuns Therapeutics..

Revenue steps up while forecasts flag earnings risk

• Revenue across the last three reported halves moved from C¥44.9 million in 1H 2024 to C¥113.9 million in 2H 2024 and C¥206.5 million in 1H 2025. Forecast data points to revenue growth of about 10.9% per year alongside a 31.2% per year projected decline in earnings over the next three years.
• Analysts watching the more cautious side of the story point out that this mix of higher recent revenue and forecast earnings decline creates a clear tension between the growth and risk signals.
  • On one hand, the move to C¥806.9 million in trailing twelve month revenue and a C¥307.4 million profit supports the view that the company became profitable over the last year.
  • On the other hand, the expectation of a 31.2% per year drop in earnings even with revenue growth means bears can argue that margin pressure or higher costs could weigh on future profit figures.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Qyuns Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

The mix of risks and rewards in this story is hard to ignore, so check the data yourself and decide where you stand by reviewing the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Qyuns Therapeutics combines recent profitability with forecasts of a 31.2% per year earnings decline and a loss in 1H 2025, which raises concerns about consistency.

If that kind of earnings uncertainty leaves you cautious, you may want to compare it with companies screened for resilient balance sheets and fundamentals using the solid balance sheet and fundamentals stocks screener (384 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com